Iovance Biotherapeutics Inc IOVA 深 滬
已收盤 08-07 16:00:00 美东时间
6.34
+0.130
+2.09%
華盛通- 最 高6.92
- 今 開6.57
- 成交量 3096.48万股
- 最 低 5.88
- 昨 收 6.21
- 總市值 28.31亿
- 52周最高 6.92
- 市盈率 靜 --
- 換手率 6.93%
- 52周最低 1.76
- 委 比 13.20%
- 總股本 4.47亿
- 歷史最高 54.208
- 量 比 1.17
- 振 幅 16.75%
- 歷史最低 1.6385
- 每 手 1
- 風險率 0.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 心血管药企Braveheart Bio上市首周大升66.7%；多只绩优股飙升！IOVA周升逾55.8%，Atlassian周升逾47%
心血管药企Braveheart Bio上市首周大升66.7%；多只绩优股飙升！IOVA周升逾55.8%，季报营收创新高；Atlassian周升逾47%，第四财季营收同比增长27.6%>>
08-08 09:48
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $11 to $13.
08-08 02:37
美股牛股 | 心血管药企BRVE上市首日飙涨逾65%，超预期募资3.8亿美元；IOVA大涨逾43%，赫兹租车涨近30%
心血管药企BRVE上市首日飙涨逾65%，超预期募资3.8亿美元；IOVA大涨逾43%，Q2亏损大幅收窄；赫兹租车涨近30%，Q2净利实现扭亏为盈>>
08-07 18:53
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
08-06 23:34
Iovance surges as Amtagvi powers Q2 beat
Iovance Biotherapeutics (IOVA) climbed more than 40% to reach a new 52-week high on Thursday after the company kept its revenue outlook under review following a Q2 2026 print that well surpassed Stree...
08-06 22:19
财报速睇 | Iovance Biotherapeutics 2026财年Q2营收0.99亿美元，同比增长65.0%；归母净利润亏损0.47亿美元，同比亏损缩窄58.0%
华盛资讯8月6日讯，Iovance Biotherapeutics公布2026财年Q2业绩，公司Q2营收0.99亿美元，同比增长65.0%，归母净利润亏损0.47亿美元，同比亏损缩窄58.0%。
08-06 21:32
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est
Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.
08-06 19:11
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
Iovance Biotherapeutics, a biotech company specializing in TIL therapies for cancer, will host a conference call on August 6, 2026, at 8:30 a.m. ET to discuss its Q2 2026 financial results and updates. The event will be available via webcast, accessible through the company’s website or the provided link. Iovance, a leader in TIL therapies, has developed Amtagvi®, the first FDA-approved T cell therapy for solid tumors. The company is committed to ...
07-30 12:00
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
07-22 01:35
